A Dose Ranging Study Evaluating Efficacy and Safety of NI-03
Conditions
Diseases of the Digestive System - Pancreas | Diseases of the Endocrine System
Phase I-II
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this study is to determine the safety and efficacy of NI-03.
- Ages18 years - 85 years
- GenderBoth
- Trial withStason Pharmaceuticals, Inc.
- Start Date03/01/2020
- End Date07/31/2018
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Last Updated07/15/2021
- Study HIC#2000023420